Mounjaro, Zepbound and compounded tirzepatide, side by side
| Product | What it is | FDA-approved for | Doses | Price |
|---|---|---|---|---|
| Mounjaro | Tirzepatide, made by Eli Lilly; first approved May 13, 2022 | Blood-sugar control in type 2 diabetes (adults and children 10 and older); lowering heart attack and stroke risk in adults with type 2 diabetes at high heart risk | 2.5, 5, 7.5, 10, 12.5 and 15 mg, once a week | List price $1,112.16 per 4-pen fill (Eli Lilly, Nov 5, 2026) |
| Zepbound | Tirzepatide, made by Eli Lilly; approved Nov 8, 2023 | Weight loss in adults with a BMI of 30+, or 27+ with a weight-related condition; moderate to severe sleep apnea in adults with obesity (since Dec 20, 2024) | 2.5, 5, 7.5, 10, 12.5 and 15 mg, once a week | From $373/mo: 2.5 mg KwikPen $299 (higher doses $399-$699) + Ro Body membership $74/mo on a 12-month prepaid plan ($149 month to month), at Ro |
| Compounded tirzepatide | Tirzepatide prepared by a licensed compounding pharmacy from a prescription | Not FDA-approved; prescribed by a clinician for weight loss | Set by the prescriber; many programs charge one price at every dose | From $96/mo (12-month plan) at yourEra |
Approvals: FDA Drug Trials Snapshot for Mounjaro (approved May 13, 2022) and FDA press releases of Nov 8, 2023 (Zepbound) and Dec 20, 2024 (Zepbound for sleep apnea); indications and strengths from the Mounjaro label (revised Aug 2026) and the Zepbound label. Mounjaro list price from Eli Lilly's pricing page, shown as a reference only. Program prices read on each program's own site, Nov 12, 2026; lowest plan shown, conditions on the cards above.
Mounjaro vs. Zepbound: one molecule, two labels
When the FDA approved Zepbound in November 2023, it noted that tirzepatide was "already approved under the trade name Mounjaro" for type 2 diabetes. The pens hold the same drug at the same strengths. What differs is the label: what the FDA approved each brand to treat, after different trials. Mounjaro's trials were in people with type 2 diabetes. Zepbound's main trial, SURMOUNT-1, was in adults with obesity, or overweight plus a weight-related condition, without diabetes; on the 15 mg dose, mean weight loss was 20.9% at 72 weeks vs 3.1% on placebo (Zepbound label, all randomized patients, treatment-regimen estimand).
The label matters for insurance: Mounjaro is approved for type 2 diabetes, so plans generally ask for that diagnosis; Zepbound coverage depends on whether your plan covers weight-loss drugs, or covers it for sleep apnea.
Is compounded tirzepatide the same as Mounjaro?
No. It contains tirzepatide, but it is a different product: a pharmacy prepares it for you from a prescription, usually as a vial you draw with a syringe, sometimes with an added vitamin such as B6 or B12. It is not FDA-approved, the FDA does not review it before it is sold, and it was not the product tested in the trials. People choose it for the price: 16 programs we compare sell it, from $96 to $399 a month (Nov 12, 2026).
The accurate name is "compounded tirzepatide", not "generic Mounjaro". There is no FDA-approved generic tirzepatide in the US.
Which one to ask for
- Type 2 diabetes: Mounjaro is the brand your plan is most likely to cover; ask your own doctor or plan first.
- Weight loss without diabetes: Zepbound is the tirzepatide brand approved for it, from $373 a month at Ro (2.5 mg KwikPen $299, higher doses $399-$699, plus the Ro Body membership: $74/mo on a 12-month prepaid plan, $149 month to month).
- Paying yourself: compounded tirzepatide costs the least, $96 a month on yourEra's 12-month plan ($1,152 billed upfront).
The online clinician decides which one fits your health. Several programs sell both a brand and compounded tirzepatide, so you can change later with the same care team.







